IMO it has to be multidosing in short periods of time, all single dose trials had positive outcomes.Or the Phase 1 group for a reason I can't figure out. But that's not my first thought either.
IMO it has to be multidosing in short periods of time, all single dose trials had positive outcomes.Or the Phase 1 group for a reason I can't figure out. But that's not my first thought either.
I don't think they will lie. A lot of well known people left their old jobs to join Frequency Therapeutics believing FX-322 works. I still believe in it because Phase 1b for both trials showed improvement in word scores which has never been done before.Shady? As in FREQ lying? I don't think that's the case.
To be honest, and I don't say this to sound conceited but rather to add substantively, I don't know why they didn't calculate the p-values like I did. I actually wonder if they just sort of said "well, Thornton and Raffin margin of errors are used all the time. Let's go to the table and find the values." Granted, there are some (definitely not that farfetched) assumptions in the modeling approach, but those p-values help to illuminate the rarity of the situation. Besides, if you're going to use Thornton Raffin confidence intervals anyways, it's an immediately logical thing to calculate the p-values under the same setting. In other words, a bear could beat up the use of a Binomial Model, but whatever their critique is, it would apply to the confidence intervals and the p-values. If you're going to live by these clinical guidelines, at least add more evidence for your arguments.That's beyond "lucky" statistically. I would say there is something shady going on if those effects turn out to be only ever seen in Phase 1.
But FREQ has reviewed those trials, as has the FDA. Surely if there was such a discrepancy after the unblinding, either or both of them would have caught them.To be honest, and I don't say this to sound conceited but rather to add substantively, I don't know why they didn't calculate the p-values like I did. I actually wonder if they just sort of said "well, Thornton and Raffin margin of errors are used all the time. Let's go to the table and find the values." Granted, there are some (definitely not that farfetched) assumptions in the modeling approach, but those p-values help to illuminate the rarity of the situation. Besides, if you're going to use Thornton Raffin confidence intervals anyways, it's an immediately logical thing to calculate the p-values under the same setting. In other words, a bear could beat up the use of a Binomial Model, but whatever their critique is, it would apply to the confidence intervals and the p-values. If you're going to live by these clinical guidelines, at least add more evidence for your arguments.
I don't think most people understand just how ridiculous it is for the same person with the same hearing to go from 40% to 78%. And then you had three people like this. Where you and I agree is that there's not a doubt in my mind that there's no way those 3 were standard situations of getting lucky. At least 1 person was helped by the drug or at least 1 person had deflated scores at baseline. Even as a bear, I accept that.
A natural question is then, what's the probability that the 3 superstars landed in the FX-322 group?
In a sample of n=23, with 15 in FX-322 and 8 in placebo, it ends up being 25.7%. That's not that low. In other words, if we worked under the assumption that all of the 3 superstars were baseline fakers, there's still a 25.7% chance that they all landed in the FX-322 group.
Sadly, even Phase 1/2 can be questioned, but the questioning is not "was it chance?"
In total agreement. It's not placebo and not chance. But we can't *totally* rule out shenanigans for reasons I can't even begin to speculate on (since depressed word scores were not a Phase 1 requirement).To be honest, and I don't say this to sound conceited but rather to add substantively, I don't know why they didn't calculate the p-values like I did. I actually wonder if they just sort of said "well, Thornton and Raffin margin of errors are used all the time. Let's go to the table and find the values." Granted, there are some (definitely not that farfetched) assumptions in the modeling approach, but those p-values help to illuminate the rarity of the situation. Besides, if you're going to use Thornton Raffin confidence intervals anyways, it's an immediately logical thing to calculate the p-values under the same setting. In other words, a bear could beat up the use of a Binomial Model, but whatever their critique is, it would apply to the confidence intervals and the p-values. If you're going to live by these clinical guidelines, at least add more evidence for your arguments.
I don't think most people understand just how ridiculous it is for the same person with the same hearing to go from 40% to 78%. And then you had three people like this. Where you and I agree is that there's not a doubt in my mind that there's no way those 3 were standard situations of getting lucky. At least 1 person was helped by the drug or at least 1 person had deflated scores at baseline. Even as a bear, I accept that.
A natural question is then, what's the probability that the 3 superstars landed in the FX-322 group?
In a sample of n=23, with 15 in FX-322 and 8 in placebo, it ends up being 25.7%. That's not that low. In other words, if we worked under the assumption that all of the 3 superstars were baseline fakers, there's still a 25.7% chance that they all landed in the FX-322 group.
Sadly, even Phase 1/2 can be questioned, but the questioning is not "was it chance?"
That's a good point. They probably did go back and look at the records of Phase 1 participants. If they didn't before, they certainly would have in the last week before releasing data.But FREQ has reviewed those trials, as has the FDA. Surely if there was such a discrepancy after the unblinding, either or both of them would have caught them.
And since they didn't mention anything about those, we have to assume both FREQ and the FDA consider them legit.That's a good point. They probably did go back and look at the records of Phase 1 participants. If they didn't before, they certainly would have in the last week before releasing data.
That's a good thought. However, a lot of it reduces back to my 25.7% calculation of the 3 superstars landing in the FX-322 group.But FREQ has reviewed those trials, as has the FDA. Surely if there was such a discrepancy after the unblinding, either or both of them would have caught them.
Yeah, assuming they did go back and review Phase 1 records carefully (I think that is a totally reasonable assumption), then Frequency Therapeutics did not find the same discrepancy there or they omitted it but instinct says Frequency Therapeutics is a company with integrity. These are long time industry veterans. I would be pretty shocked if it was fraud.And since they didn't mention anything about those, we have to assume both FREQ and the FDA consider them legit.
I'm still not clear on the entry process. The clinical trials say >=6 month stability, no more than 10 dB changes at one frequency or no more than 5 dB changes at two consecutive frequencies.Yeah, assuming they did go back and review Phase 1 records carefully (I think that is a totally reasonable assumption), then Frequency Therapeutics did not find the same discrepancy there or they omitted it but instinct says Frequency Therapeutics is a company with integrity. These are long time industry veterans. I would be pretty shocked if it was fraud.
I'm going with there is a hearing effect for sure if that's the case (and there were definitely responders in Phase 1b for word score as well. Btw, since the subjects were mild to severe in this study, it would be really interesting to compare between individuals here).
12 days? Where did you see that? I thought it took a couple of months.as McLean stated, it takes 12 days to regrow hair cells.
I agree they didn't go back through the medical records of Phase 1 at the time because, if they thought to do that, they would have had better measures in place and they could have prevented the "discrepancy" problem in Phase 2a.That's a good thought. However, a lot of it reduces back to my 25.7% calculation of the 3 superstars landing in the FX-322 group.
The investigation of the Phase 2a trials is quite different because presumably, they hope that after unblinding themselves, they can see superstar individuals in the placebo group. Then it makes sense to wonder how they became superstars under a placebo.
The issue is that there are no superstar placebos in Phase 1/2 so maybe they think it's conceivable that the superstars were helped by the drug.
I guess for Phase 1/2, they could try to look for consistent word scores >=6 months before the trial, at screening, and at baseline, but you would think if they were tracking it, they would have done a better job with Phase 2a.
What a mess. Seems like what they should have done, in hindsight, is required longer stability than >=6 months. Maybe make the time frame so long that it's unreasonable to believe the person took a faulty word test years ago, anticipating that they would be on the verge of landing in a clinical trial.
Besides, the superstars in Phase 1/2 had disease durations of 21.05, 5.23, and 1.70 years, respectively.
It seems like in all likelihood, a lot of the Phase 2a participants easily exceeded the >=6 month stability. That makes it that much more incriminating to have a trial bias since they mostly had to just do a better job of comparing screening word scores to word scores from years ago when they weren't lying.
I almost wish there could be an independent person looking for discrepancies between screen and baseline. The problem though is that however unlikely, confidence intervals only describe a high likelihood of being in them. One can break them by chance, by assumption. Yeah, deep down, we're all thinking this can't happen with hearing, but they have to operate under the assumption that it can. It's hard to remove someone from a trial just because they broke a confidence interval. Maybe it was a (assumed) 5% chance that occurred.
The "stability" part was determined by standard audiogram.I'm still not clear on the entry process. The clinical trials say >=6 month stability, no more than 10 dB changes at one frequency or no more than 5 dB changes at two consecutive frequencies.
But there's nothing about word scores. How does one even cheat? Do they really not use the Thornton and Raffin confidence intervals? Maybe even raise the alpha level to be extra rigorous. For example, if you had 80% confidence intervals comparing their >=6 month WR to their screening WR, it would be easier for there to be statistically significant differences. If there are, they get excluded from the trial. Tough luck, at least it's a rigorous standard. If someone gets falsely excluded, big deal.
Is there a sheer recruiting numbers problem with this approach? Do they not know how to calculate the 80% confidence intervals from the Thornton and Raffin paper? Maybe I'm ignorant here, but I don't see this as the world's hardest problem.
There's no way Frequency Therapeutics are frauds, but they definitely didn't just "get burned" by cheaters.
I can't remember, but someone in this thread stated that Will McLean said it takes 12 days to regrow hair cells.12 days? Where did you see that? I thought it took a couple of months.
If the two ongoing trials for age-related and severe hearing loss show improvements in word scores, it will be definite that FX-322 works and that weekly dosing of FX-322 kills the regrowing process and they need to space out the dosing even longer e.g. monthly.I still don't know if FX-322 works or not. When will it be known definitively if it works or not, and that's under the assumption that it works for tinnitus? Phase 2b hasn't shown anything definitive yet?
Here's from the clinical trial on Phase 1/2.Correct me if I'm wrong, but did I see somewhere that the severe group was only double blinded? Vs quadruple?
Actually, was Phase 1 also quadruple blinded?
Sorry but what does this mean?Here's from the clinical trial on Phase 1/2.
View attachment 44272
And for trial FX-322-113.
View attachment 44276
They both say "quadruple masking," but double-blind.
Here's what Phase 2a says.
View attachment 44274
Haha, I'm not sure, that's why I didn't comment. It says the masking is quadruple, but the titles are "Double-blind." I would think it would be quadruple blind, but I'm not sure.Sorry but what does this mean?
I'm taking a stab but maybe it means it's blinded in both directions and masked at the four different points?Haha, I'm not sure, that's why I didn't comment. It says the masking is quadruple, but the titles are "Double-blind." I would think it would be quadruple blind, but I'm not sure.
Thanks for that. That's kind of my whole point.To anyone curious, here is a very good video on the WR test from an audiologist:
Captions are available. Here's a summary of what it talks about:
- WR has nothing to do with volume. In fact, the test is given to see if one is a good hearing aid candidate. The volume of the words is chosen in such a way that the patient will have no issue hearing the words in volume. Hearing aids won't help people with this problem because hearing aids only amplify (OHC).
- Some incompetent audiologists may have used live words instead of recorded words. The test-retest stability is only reliable if it's calibrated the same both times.
- 50 questions per test is more reliable than 10 or 25 questions (duh)
For those of you wondering if effort or a true placebo can be the reason why someone genuinely improves dramatically, it doesn't make any sense since the words are played at a perfectly comfortable level. If you don't hear a word, it's because your inner hair cells or synapses are broken. Nothing can be done for it.
Of course, this doesn't change anything. We still have the problem of "Responded to the drug or deflated baseline scores without the drug helping," but it's interesting at least.
HOLY SHIT, 90 FUCKING PERCENT IMPROVEMENT!I have spoken to a patient from the Phase 2 trial. More below.
I think many of you by now know me as a member that often does deep dives and goes down rabbitholes. Ever since I first read the pre-clinical work, there was no doubt in my mind this drug was the real deal, especially after the Phase 1/2 study. For me, it was simply a question of optimising delivery and dosage. However, for the last 72 hours, I have been questioning everything I previously believed to be true. It has been a very unnerving experience to say the least, as I'm sure it has been for others. So I decided to go back and read all the preclinical work again, as well as other literature. This time I wasn't satisfied, because I realised peer-reviewed papers were no longer good enough in face of the current situation. I had planned on taking a break from the forum, but I felt the only way I could settle this one way or another, at least in my mind, was to find someone who took part in the trial.
I can confidently say that I have tracked down two patients from the clinical trial. I am in touch with one of them and waiting to hear back from the other. I went in prepared with questions and made a lot of notes from the conversation with the first patient. I shall summarise them below.
Patient X Background
Age: 55-65 (I'm avoiding giving the exact number as not to dox the patient)
Presentation: Unilateral hearing loss and bilateral tinnitus
Cause: Unknown
Treatment history: 30 injections of ITT steroids and HBO treatment
Time of onset: 2 years
Hearing aid: Yes
Patient X - FX-322 trial
Baseline WR score: 40%
Post-treatment WR score: 50%
Post-treatment audiogram: 10 dB gains in three frequency bands - two in the extended audiogram and one in the standard audiogram
Post-treatment tinnitus: 90% improvement in both ears (despite only one ear being treated) after 3.5 months
Summary
As you will infer from the above, the patient had a sudden onset of hearing loss in a single ear. This was preceded by tinnitus two weeks before onset. Following 30 injections of ITT steroids and HBO treatment, they were able to go from, for all intents and purposes, deaf to a 40% WR score baseline in the affected ear. They describe their hearing pre ITT steroids and HBO treatment as garbled and sounding like chipmunks. Although this helped regain some hearing, they still required the use of hearing aids moving forward. This was their presentation going into the trial.
Following participation in the trial, the patient saw a 10 point gain in their WR score from baseline and 10 dB gains across three different frequency bands. They started to notice their hearing improvements one month after their last injection. Interestingly, the reduction in bilateral tinnitus, came 3.5 months after the last injection - outside the scope of the interim study. They describe their stress levels induced by tinnitus as having been dramatically reduced and that their general hearing in noisier environments is "better but not perfect". Examples of sounds they say are now easier to discern include the chime on the dryer when the laundry is dry, hearing a waitress's voice in a restaurant (higher pitched female voices), soft and squeaky toys. They also have a better sense of directionality. They still, however, require the use of a hearing aid.
The patient remains blinded and unaware as to whether they received placebo or FX-322 at this moment in time, although they have kindly agreed to letting me know once they know. Similar to another anecdotal experience posted here, they described a burning sensation during 2 of the four injections. They experienced no other discomfort associated with the regularity of the injections.
When asked whether they were surprised the trial had failed, the patient said they were "shocked".
Conclusion
I'm sure some of you have questions as to how I was able to track down a patient from the trial. The answer is I can never know for sure whether this really is a patient from the trial, but what I can confirm, for whatever my word is worth on here, is that Patient X has a publicly documented history of hearing loss and a publicly documented declaration of having applied to (and entered) the trial. I don't wish to say much more than that, but I think if you read between the lines here you'll be able to figure out what I've done and I'm saying. I'm already mindful of the fact that this person has been bombarded with a lot of questions from a complete stranger (yours truly), so if there is something you want to ask, I think the best course of action would be for me to get back in touch with them directly.
I'm about to sleep so won't be able to answer any questions until tomorrow at the earliest, although I still intend to take a break for a week or so from the forum (although I am keeping general tabs on discussions). I will report back if and when I hear from the second patient.
Thank you for this. So he noticed improvements in his hearing about one month after his last FX-322 injection. Therefore this does make sense that weekly dosing of FX-322 kills the regrowing process as it takes about a month to notice the effects of the FX-322 injection at which point his tinnitus seems to have been 90% gone.I have spoken to a patient from the Phase 2 trial. More below.
I think many of you by now know me as a member that often does deep dives and goes down rabbitholes. Ever since I first read the pre-clinical work, there was no doubt in my mind this drug was the real deal, especially after the Phase 1/2 study. For me, it was simply a question of optimising delivery and dosage. However, for the last 72 hours, I have been questioning everything I previously believed to be true. It has been a very unnerving experience to say the least, as I'm sure it has been for others. So I decided to go back and read all the preclinical work again, as well as other literature. This time I wasn't satisfied, because I realised peer-reviewed papers were no longer good enough in face of the current situation. I had planned on taking a break from the forum, but I felt the only way I could settle this one way or another, at least in my mind, was to find someone who took part in the trial.
I can confidently say that I have tracked down two patients from the clinical trial. I am in touch with one of them and waiting to hear back from the other. I went in prepared with questions and made a lot of notes from the conversation with the first patient. I shall summarise them below.
Patient X Background
Age: 55-65 (I'm avoiding giving the exact number as not to dox the patient)
Presentation: Unilateral hearing loss and bilateral tinnitus
Cause: Unknown
Treatment history: 30 injections of ITT steroids and HBO treatment
Time of onset: 2 years
Hearing aid: Yes
Patient X - FX-322 trial
Baseline WR score: 40%
Post-treatment WR score: 50%
Post-treatment audiogram: 10 dB gains in three frequency bands - two in the extended audiogram and one in the standard audiogram
Post-treatment tinnitus: 90% improvement in both ears (despite only one ear being treated) after 3.5 months
Summary
As you will infer from the above, the patient had a sudden onset of hearing loss in a single ear. This was preceded by tinnitus two weeks before onset. Following 30 injections of ITT steroids and HBO treatment, they were able to go from, for all intents and purposes, deaf to a 40% WR score baseline in the affected ear. They describe their hearing pre ITT steroids and HBO treatment as garbled and sounding like chipmunks. Although this helped regain some hearing, they still required the use of hearing aids moving forward. This was their presentation going into the trial.
Following participation in the trial, the patient saw a 10 point gain in their WR score from baseline and 10 dB gains across three different frequency bands. They started to notice their hearing improvements one month after their last injection. Interestingly, the reduction in bilateral tinnitus, came 3.5 months after the last injection - outside the scope of the interim study. They describe their stress levels induced by tinnitus as having been dramatically reduced and that their general hearing in noisier environments is "better but not perfect". Examples of sounds they say are now easier to discern include the chime on the dryer when the laundry is dry, hearing a waitress's voice in a restaurant (higher pitched female voices), soft and squeaky toys. They also have a better sense of directionality. They still, however, require the use of a hearing aid.
The patient remains blinded and unaware as to whether they received placebo or FX-322 at this moment in time, although they have kindly agreed to letting me know once they know. Similar to another anecdotal experience posted here, they described a burning sensation during 2 of the four injections. They experienced no other discomfort associated with the regularity of the injections.
When asked whether they were surprised the trial had failed, the patient said they were "shocked".
Conclusion
I'm sure some of you have questions as to how I was able to track down a patient from the trial. The answer is I can never know for sure whether this really is a patient from the trial, but what I can confirm, for whatever my word is worth on here, is that Patient X has a publicly documented history of hearing loss and a publicly documented declaration of having applied to (and entered) the trial. I don't wish to say much more than that, but I think if you read between the lines here you'll be able to figure out what I've done and I'm saying. I'm already mindful of the fact that this person has been bombarded with a lot of questions from a complete stranger (yours truly), so if there is something you want to ask, I think the best course of action would be for me to get back in touch with them directly.
I'm about to sleep so won't be able to answer any questions until tomorrow at the earliest, although I still intend to take a break for a week or so from the forum (although I am keeping general tabs on discussions). I will report back if and when I hear from the second patient.
Yeah, but this is the first time you pulled out an actual rabbit.I think many of you by now know me as a member that often does deep dives and goes down rabbitholes
Thank you. They say there are 5 stages of grief. I'm going to be stuck on stage 1 (aka denial) forever with this FX-322...I have spoken to a patient from the Phase 2 trial. More below.
I think many of you by now know me as a member that often does deep dives and goes down rabbitholes. Ever since I first read the pre-clinical work, there was no doubt in my mind this drug was the real deal, especially after the Phase 1/2 study. For me, it was simply a question of optimising delivery and dosage. However, for the last 72 hours, I have been questioning everything I previously believed to be true. It has been a very unnerving experience to say the least, as I'm sure it has been for others. So I decided to go back and read all the preclinical work again, as well as other literature. This time I wasn't satisfied, because I realised peer-reviewed papers were no longer good enough in face of the current situation. I had planned on taking a break from the forum, but I felt the only way I could settle this one way or another, at least in my mind, was to find someone who took part in the trial.
I can confidently say that I have tracked down two patients from the clinical trial. I am in touch with one of them and waiting to hear back from the other. I went in prepared with questions and made a lot of notes from the conversation with the first patient. I shall summarise them below.
Patient X Background
Age: 55-65 (I'm avoiding giving the exact number as not to dox the patient)
Presentation: Unilateral hearing loss and bilateral tinnitus
Cause: Unknown
Treatment history: 30 injections of ITT steroids and HBO treatment
Time of onset: 2 years
Hearing aid: Yes
Patient X - FX-322 trial
Baseline WR score: 40%
Post-treatment WR score: 50%
Post-treatment audiogram: 10 dB gains in three frequency bands - two in the extended audiogram and one in the standard audiogram
Post-treatment tinnitus: 90% improvement in both ears (despite only one ear being treated) after 3.5 months
Summary
As you will infer from the above, the patient had a sudden onset of hearing loss in a single ear. This was preceded by tinnitus two weeks before onset. Following 30 injections of ITT steroids and HBO treatment, they were able to go from, for all intents and purposes, deaf to a 40% WR score baseline in the affected ear. They describe their hearing pre ITT steroids and HBO treatment as garbled and sounding like chipmunks. Although this helped regain some hearing, they still required the use of hearing aids moving forward. This was their presentation going into the trial.
Following participation in the trial, the patient saw a 10 point gain in their WR score from baseline and 10 dB gains across three different frequency bands. They started to notice their hearing improvements one month after their last injection. Interestingly, the reduction in bilateral tinnitus, came 3.5 months after the last injection - outside the scope of the interim study. They describe their stress levels induced by tinnitus as having been dramatically reduced and that their general hearing in noisier environments is "better but not perfect". Examples of sounds they say are now easier to discern include the chime on the dryer when the laundry is dry, hearing a waitress's voice in a restaurant (higher pitched female voices), soft and squeaky toys. They also have a better sense of directionality. They still, however, require the use of a hearing aid.
The patient remains blinded and unaware as to whether they received placebo or FX-322 at this moment in time, although they have kindly agreed to letting me know once they know. Similar to another anecdotal experience posted here, they described a burning sensation during 2 of the four injections. They experienced no other discomfort associated with the regularity of the injections.
When asked whether they were surprised the trial had failed, the patient said they were "shocked".
Conclusion
I'm sure some of you have questions as to how I was able to track down a patient from the trial. The answer is I can never know for sure whether this really is a patient from the trial, but what I can confirm, for whatever my word is worth on here, is that Patient X has a publicly documented history of hearing loss and a publicly documented declaration of having applied to (and entered) the trial. I don't wish to say much more than that, but I think if you read between the lines here you'll be able to figure out what I've done and I'm saying. I'm already mindful of the fact that this person has been bombarded with a lot of questions from a complete stranger (yours truly), so if there is something you want to ask, I think the best course of action would be for me to get back in touch with them directly.
I'm about to sleep so won't be able to answer any questions until tomorrow at the earliest, although I still intend to take a break for a week or so from the forum (although I am keeping general tabs on discussions). I will report back if and when I hear from the second patient.